Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LTRN 
Lantern Pharma Inc (LTRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LTRN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.14% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.85M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta 1.59 | 52 Weeks Range 2.55 - 6.12 | Updated Date 08/29/2025 |
52 Weeks Range 2.55 - 6.12 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.53 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.35% | Return on Equity (TTM) -88.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27980903 | Price to Sales(TTM) - |
Enterprise Value 27980903 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 10799400 | Shares Floating 8202373 |
Shares Outstanding 10799400 | Shares Floating 8202373 | ||
Percent Insiders 14.09 | Percent Institutions 20.96 |
Upturn AI SWOT
Lantern Pharma Inc
Company Overview
History and Background
Lantern Pharma Inc. was founded in 2013 and went public in 2020. It focuses on using artificial intelligence (AI) and machine learning to rescue, revive, and repurpose failed or abandoned cancer therapies, aiming to develop more targeted and effective treatments.
Core Business Areas
- AI-Powered Drug Discovery Platform: Development and use of RADRu00ae, an AI platform, to predict drug response biomarkers and identify patient populations most likely to respond to therapies.
- Drug Development: Clinical development of a portfolio of drug candidates focusing on precision oncology and targeted therapies for various cancers.
Leadership and Structure
Panna Sharma serves as the President and CEO. The company has a board of directors overseeing strategic direction and governance.
Top Products and Market Share
Key Offerings
- LP-300: A repurposed drug candidate being developed for non-small cell lung cancer. It is in Phase 2 clinical trials. Competitors in this area include companies developing targeted therapies for NSCLC, such as AstraZeneca (AZN) with Tagrisso and Roche (RHHBY) with Alecensa. No market share data is publicly available for LP-300 at this stage.
- LP-184: A repurposed drug candidate being developed for several cancer types, including pancreatic cancer and glioblastoma. It is in preclinical and Phase 1 clinical trials. Competitors in the pancreatic cancer space include companies developing therapies such as Celgene (now Bristol Myers Squibb) (BMY) and Novartis (NVS). No market share data is publicly available for LP-184 at this stage.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the oncology segment, is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Precision oncology is a growing area, focusing on targeted therapies based on individual patient characteristics.
Positioning
Lantern Pharma is positioned as a precision oncology company leveraging AI to accelerate drug development and improve treatment outcomes. Its competitive advantage lies in its AI platform, RADRu00ae, which aims to identify optimal patient populations and reduce development risks.
Total Addressable Market (TAM)
The global oncology market is estimated to reach over $400 billion by 2030. Lantern Pharma is targeting specific cancer subtypes within this vast market, aiming to capture a portion of the precision oncology segment, which is experiencing significant growth.
Upturn SWOT Analysis
Strengths
- AI-driven drug discovery platform (RADRu00ae)
- Repurposing existing drugs to reduce development timelines and costs
- Focus on precision oncology and targeted therapies
- Experienced management team
- Partnerships with research institutions and pharmaceutical companies
Weaknesses
- Limited number of drugs in late-stage clinical development
- High dependence on the success of its AI platform
- Reliance on fundraising for operations
- Relatively small company size compared to major pharmaceutical players
- Shares Outstanding: Volatile
Opportunities
- Expanding the application of RADRu00ae to other therapeutic areas
- Securing partnerships with larger pharmaceutical companies
- Advancing drug candidates through clinical trials and regulatory approval
- Acquiring or in-licensing promising drug candidates
- Growing demand for precision oncology therapies
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from larger pharmaceutical companies with more resources
- Patent challenges and intellectual property protection issues
- Changes in reimbursement policies and healthcare regulations
Competitors and Market Share
Key Competitors
- AZN
- BMY
- NVS
Competitive Landscape
Lantern Pharma's advantage lies in its AI platform, RADRu00ae. However, it faces intense competition from larger pharmaceutical companies with significantly greater financial resources and established drug pipelines. To succeed, Lantern Pharma needs to demonstrate the clinical efficacy and cost-effectiveness of its AI-driven approach.
Growth Trajectory and Initiatives
Historical Growth: Lantern Pharma's historical growth has been driven by advancements in its AI platform and the progress of its drug candidates through clinical trials.
Future Projections: Future growth projections depend on the success of its drug candidates in clinical trials and regulatory approval. Analyst estimates vary and can be found on financial websites. Generally, approval of one of their leading drugs could substantially improve growth.
Recent Initiatives: Recent initiatives include expanding the RADRu00ae platform, advancing LP-300 and LP-184 through clinical trials, and forming partnerships with research institutions.
Summary
Lantern Pharma is an early-stage, AI-driven precision oncology company with promising technology but faces high execution risk. Its strength lies in its RADRu00ae platform, but the company needs to advance its drug candidates through clinical trials successfully. Significant challenges include competition from larger pharmaceutical companies and the need to raise capital to fund its operations. The company needs to secure partnerships and demonstrate clinical success to ensure future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lantern Pharma Inc. SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantern Pharma Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-06-11 | President, CEO & Director Mr. Panna Sharma | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.lanternpharma.com |
Full time employees 24 | Website https://www.lanternpharma.com | ||
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.